Luigi De Petris
Karolinska University Hospital · 156 works · 4,399 citations · h-index 30
Top works
- Second-Line Treatment of Advanced Non-small Cell Lung Cancer
- Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
- Caring for patients with cancer in the COVID-19 era
- Predicting Radiation Pneumonitis After Chemoradiation Therapy for Lung Cancer: An International Individual Patient Data Meta-analysis
- Treatment of Advanced Non–Small-Cell Lung Cancer in the Elderly: Results of an International Expert Panel
- Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK -Positive Non–Small-Cell Lung Cancer
- ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
- The role of p53 in treatment responses of lung cancer
- Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK -positive Non-Small Cell Lung Cancer
- Clinical Drug–Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib
- Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology
- Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer
- The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology
- Treatment of advanced non-small cell lung cancer
- Role of Gross Tumor Volume on Outcome and of Dose Parameters on Toxicity of Patients Undergoing Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer
- Effect of corticosteroids on the outcome of patients with advanced non–small cell lung cancer treated with immune-checkpoint inhibitors
- Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal
- ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016
- Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673).
- Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer